CY1114644T1 - Χρηση ραδιοεπισημασμενων παραγωγων θειοφλαβινης στην απεικονιση αμυλοειδους για την αξιολογηση αντι-αμυλοειδικων θεραπειων - Google Patents
Χρηση ραδιοεπισημασμενων παραγωγων θειοφλαβινης στην απεικονιση αμυλοειδους για την αξιολογηση αντι-αμυλοειδικων θεραπειωνInfo
- Publication number
- CY1114644T1 CY1114644T1 CY20131100776T CY131100776T CY1114644T1 CY 1114644 T1 CY1114644 T1 CY 1114644T1 CY 20131100776 T CY20131100776 T CY 20131100776T CY 131100776 T CY131100776 T CY 131100776T CY 1114644 T1 CY1114644 T1 CY 1114644T1
- Authority
- CY
- Cyprus
- Prior art keywords
- amyloid
- patient
- thioplavine
- formula
- radiated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58448704P | 2004-07-02 | 2004-07-02 | |
EP05787557.7A EP1771208B1 (en) | 2004-07-02 | 2005-07-01 | Use of thioflavin radiolabeled derivatives in amyloid imaging for assessing anti-amyloid therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114644T1 true CY1114644T1 (el) | 2016-10-05 |
Family
ID=35504952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100776T CY1114644T1 (el) | 2004-07-02 | 2013-09-10 | Χρηση ραδιοεπισημασμενων παραγωγων θειοφλαβινης στην απεικονιση αμυλοειδους για την αξιολογηση αντι-αμυλοειδικων θεραπειων |
Country Status (16)
Country | Link |
---|---|
US (4) | US8147798B2 (pt-PT) |
EP (1) | EP1771208B1 (pt-PT) |
JP (1) | JP2008505115A (pt-PT) |
CN (2) | CN101137397A (pt-PT) |
AU (1) | AU2005270026A1 (pt-PT) |
BR (1) | BRPI0512893B8 (pt-PT) |
CA (2) | CA2830939C (pt-PT) |
CY (1) | CY1114644T1 (pt-PT) |
DK (1) | DK1771208T3 (pt-PT) |
ES (1) | ES2427963T3 (pt-PT) |
NO (1) | NO339187B1 (pt-PT) |
PL (1) | PL1771208T3 (pt-PT) |
PT (1) | PT1771208E (pt-PT) |
RU (1) | RU2007104107A (pt-PT) |
SI (1) | SI1771208T1 (pt-PT) |
WO (1) | WO2006014381A2 (pt-PT) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
PL215711B1 (pl) * | 2000-08-24 | 2014-01-31 | Univ Pittsburgh | Nowe zwiazki pochodne tioflawiny, sposób syntezy zwiazków i ich zastosowanie, kompozycja farmaceutyczna zawierajaca zwiazki i zastosowanie kompozycji |
US7270800B2 (en) * | 2000-08-24 | 2007-09-18 | University Of Pittsburgh | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
WO2004069182A2 (en) * | 2003-02-01 | 2004-08-19 | Neuralab Limited | Active immunization to generate antibodies to soluble a-beta |
US8236282B2 (en) | 2003-08-22 | 2012-08-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | Benzothiazole derivative compounds, compositions and uses |
WO2006066089A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
GB0516564D0 (en) * | 2005-08-12 | 2005-09-21 | Ge Healthcare Ltd | Fluorination process |
WO2007035405A2 (en) * | 2005-09-16 | 2007-03-29 | University Of Pittsburgh | In-vivo and in-vitro method for detecting amyloid deposits having at least one amyloidogenic protein |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US7700616B2 (en) | 2006-05-08 | 2010-04-20 | Molecular Neuroimaging, Llc. | Compounds and amyloid probes thereof for therapeutic and imaging uses |
TW200813035A (en) | 2006-06-19 | 2008-03-16 | Astrazeneca Ab | Novel heteroaryl substituted benzoxazoles |
CN101293878B (zh) * | 2007-04-25 | 2010-12-15 | 中国科学院上海应用物理研究所 | 苯并噻唑苯胺类化合物及其制备方法和应用 |
PL2182983T3 (pl) * | 2007-07-27 | 2014-10-31 | Janssen Alzheimer Immunotherap | Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta |
WO2009027452A2 (en) * | 2007-08-30 | 2009-03-05 | Ge Healthcare Limited | Radiopharmaceutical composition |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
JP5603855B2 (ja) | 2008-04-04 | 2014-10-08 | アビッド レディオファーマシューティカルズ、インク. | 神経変成疾患の放射性薬剤による画像化 |
RU2518892C2 (ru) * | 2008-09-23 | 2014-06-10 | Виста Лабораториз Лтд. | Лиганды для агрегированных молекул тау-белка |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
WO2010053218A1 (en) * | 2008-11-06 | 2010-05-14 | Snu R&Db Foundation | Fluorinated benzothiazole derivatives, preparation method thereof and imaging agent for diagnosing altzheimer's disease using the same |
JP2013521233A (ja) * | 2010-02-25 | 2013-06-10 | ヤンセン アルツハイマー イミュノセラピー | Aβを標的とする免疫療法のPETモニタリング |
WO2014004664A2 (en) * | 2012-06-27 | 2014-01-03 | Mayo Foundation For Medical Education And Research | Treatment of meningiomas using phenylbenzothiazole, stilbene, biphenylalkyne, or pyridine derivatives |
US9422286B2 (en) | 2014-01-27 | 2016-08-23 | Washington University | Metal-binding bifunctional compounds as diagnostic agents for Alzheimer's disease |
AU2016308189B2 (en) * | 2015-08-18 | 2021-03-11 | The Regents Of The University Of California | Nitroxide containing amyloid binding agents for imaging and therapeutic uses |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030092003A1 (en) * | 1999-12-29 | 2003-05-15 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of Alzheimer's disease |
PL215711B1 (pl) * | 2000-08-24 | 2014-01-31 | Univ Pittsburgh | Nowe zwiazki pochodne tioflawiny, sposób syntezy zwiazków i ich zastosowanie, kompozycja farmaceutyczna zawierajaca zwiazki i zastosowanie kompozycji |
US7270800B2 (en) * | 2000-08-24 | 2007-09-18 | University Of Pittsburgh | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
DE60217090T2 (de) * | 2001-04-23 | 2007-07-12 | The Trustees Of The University Of Pennsylvania | Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel |
GB0130305D0 (en) | 2001-12-19 | 2002-02-06 | Amersham Plc | Compounds for imaging alzheimers disease |
JP2005523903A (ja) | 2002-02-13 | 2005-08-11 | アメルシャム・パブリック・リミテッド・カンパニー | アミロイド斑の生体内撮像用のベンゾチアゾール誘導体 |
CA2438032C (en) | 2003-03-14 | 2013-05-07 | University Of Pittsburgh | Benzothiazole derivative compounds, compositions and uses |
GB0307855D0 (en) | 2003-04-04 | 2003-05-14 | Novartis Ag | Organic compounds |
BRPI0512932A (pt) * | 2004-07-02 | 2008-04-15 | Univ Pittsburgh | compostos e métodos de identificação e de diagnóstico de paciente como prodrÈmico para doença associada com a deposição amilóide |
-
2005
- 2005-07-01 PL PL05787557T patent/PL1771208T3/pl unknown
- 2005-07-01 WO PCT/US2005/023617 patent/WO2006014381A2/en active Application Filing
- 2005-07-01 DK DK05787557.7T patent/DK1771208T3/da active
- 2005-07-01 SI SI200531765T patent/SI1771208T1/sl unknown
- 2005-07-01 ES ES05787557T patent/ES2427963T3/es active Active
- 2005-07-01 CN CNA2005800263010A patent/CN101137397A/zh active Pending
- 2005-07-01 AU AU2005270026A patent/AU2005270026A1/en not_active Abandoned
- 2005-07-01 PT PT57875577T patent/PT1771208E/pt unknown
- 2005-07-01 US US11/666,083 patent/US8147798B2/en active Active
- 2005-07-01 CN CN2012104014697A patent/CN102973954A/zh active Pending
- 2005-07-01 JP JP2007519500A patent/JP2008505115A/ja active Pending
- 2005-07-01 CA CA2830939A patent/CA2830939C/en active Active
- 2005-07-01 EP EP05787557.7A patent/EP1771208B1/en active Active
- 2005-07-01 CA CA2587248A patent/CA2587248C/en active Active
- 2005-07-01 RU RU2007104107/04A patent/RU2007104107A/ru not_active Application Discontinuation
- 2005-07-01 BR BRPI0512893A patent/BRPI0512893B8/pt active IP Right Grant
-
2007
- 2007-01-31 NO NO20070593A patent/NO339187B1/no unknown
-
2012
- 2012-03-06 US US13/412,823 patent/US8343457B2/en active Active
- 2012-10-23 US US13/658,483 patent/US8580229B2/en active Active
-
2013
- 2013-09-10 CY CY20131100776T patent/CY1114644T1/el unknown
- 2013-10-09 US US14/050,018 patent/US20140105820A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SI1771208T1 (sl) | 2013-10-30 |
US20130045164A1 (en) | 2013-02-21 |
NO339187B1 (no) | 2016-11-14 |
CN102973954A (zh) | 2013-03-20 |
US20140105820A1 (en) | 2014-04-17 |
WO2006014381A2 (en) | 2006-02-09 |
ES2427963T3 (es) | 2013-11-05 |
CA2587248C (en) | 2014-01-07 |
EP1771208A2 (en) | 2007-04-11 |
US8343457B2 (en) | 2013-01-01 |
BRPI0512893A (pt) | 2008-04-15 |
RU2007104107A (ru) | 2008-08-10 |
US8147798B2 (en) | 2012-04-03 |
CA2830939C (en) | 2017-02-28 |
NO20070593L (no) | 2007-03-27 |
WO2006014381A9 (en) | 2006-04-13 |
PT1771208E (pt) | 2013-09-24 |
WO2006014381A3 (en) | 2007-01-18 |
BRPI0512893B1 (pt) | 2019-12-24 |
CA2587248A1 (en) | 2006-02-09 |
DK1771208T3 (da) | 2013-09-02 |
CA2830939A1 (en) | 2006-02-09 |
PL1771208T3 (pl) | 2013-11-29 |
AU2005270026A1 (en) | 2006-02-09 |
US20080219931A1 (en) | 2008-09-11 |
EP1771208B1 (en) | 2013-06-19 |
BRPI0512893B8 (pt) | 2021-07-27 |
US8580229B2 (en) | 2013-11-12 |
US20120177572A1 (en) | 2012-07-12 |
JP2008505115A (ja) | 2008-02-21 |
CN101137397A (zh) | 2008-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1114644T1 (el) | Χρηση ραδιοεπισημασμενων παραγωγων θειοφλαβινης στην απεικονιση αμυλοειδους για την αξιολογηση αντι-αμυλοειδικων θεραπειων | |
CY1123110T1 (el) | Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου | |
CY1119224T1 (el) | Αποτελεσματικη θεραπευτικη αγωγη ογκων και καρκινου με φωσφορικη τρισιριβινη | |
CY1122428T1 (el) | Θεραπευτικη αγωγη της παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας με διειδικα αντισωματα εναντι cd3xcd19 | |
CY1118549T1 (el) | Χρηση anti-vegf αντισωματος σε συνδυασμο με χημειοθεραπεια για τη θεραπευτικη αγωγη του καρκινου του μαστου | |
CY1121330T1 (el) | Συνθεσεις που περιλαμβανουν αζελαστινη και μεθοδοι χρησης αυτων | |
CY1123388T1 (el) | Υποκατεστημενου νικοτινιμιδιου αναστολεις της βτκ και παρασκευη αυτων και χρηση στη θεραπεια καρκινου, φλεγμονης και αυτοανοσης ασθενειας | |
CY1117916T1 (el) | Θεραπεια διαταραχων που σχετιζονται me bdnf χρησιμοποιωντας laquinimod | |
CY1121628T1 (el) | 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης | |
CY1110889T1 (el) | C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους | |
CY1116041T1 (el) | Μεσα και μεθοδοι για τη θεραπευτικη αγωγη νεοπλασματικων νοσων | |
CY1121288T1 (el) | Μεθοδος αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας | |
CY1117897T1 (el) | Αναστολεις κινασης τυροσινης bruton | |
CY1118660T1 (el) | Συνθεσεις και μεθοδοι για την θεραπεια διαταραχων ματιων | |
CY1117154T1 (el) | Συνθεσεις και μεθοδοι για τη διαγνωση και αγωγη του καρκινου | |
CY1113058T1 (el) | Συνδυαστικη θεραπεια για την αντιμετωπιση οφθαλμικων νεοαγγειακων διαταραχων | |
CY1108421T1 (el) | Η χρηση σκευασματων μελοξικαμης στην κτηνιατρικη | |
CR9933A (es) | Agentes que se enlazan con un objetivo en el tejido pulmonar para el tratamiento de enfermedades respiratorias | |
CY1108436T1 (el) | Χορηγηση καψαϊκινοειδων | |
CY1112473T1 (el) | Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα | |
CY1114040T1 (el) | Συνδυαστικη θεραπεια του καρκινου περιλαμβανουσα αναστολεις των egfr/her2 | |
CY1110495T1 (el) | Χρηση ενος αγωνιστη υποδοχεα nmda για τη θεραπεια εμβοης που προκαλειται απο κοχλιακη διεγερτοτοξικοτητα | |
CY1121474T1 (el) | Συνδυασμος αντιϊικων παραγοντων αμεσης δρασης και ριμπαβιρινης για την θεραπευτικη αγωγη ασθενων me hcv | |
CY1106283T1 (el) | Κινολινυλ-πυρρολοπυραζολες | |
CY1110162T1 (el) | Φαρμακοτεχνικη μορφη και μεθοδοι για την αγωγη της θρομβοκυτταραιμιας |